Array BioPharma hires vp of clinical sciences

Karsten Witt will lead clinical science and drug safety activities

Karsten Witt has joined Array BioPharma of Boulder, Colorado, US as vp of clinical sciences. With 26 years of experience in medicine and 19 years working in the pharmaceutical industry, Dr Witt will lead clinical science and drug safety activities for Array's pipeline of small molecule drugs to treat cancer and inflammatory diseases.

‘Karsten brings valuable experience to Array to help us move our proprietary pipeline to the next level,’ said chief executive Robert Conway. ‘His expertise in advancing therapeutics for cancer and inflammation, including the registration of Tarceva (erlotinib), will enable him to make immediate contributions to our proprietary programmes as we move into pivotal studies.’

From 2002 until he joined Array, Witt served as senior vp, Pharmaceutical Operations at OSI Pharmaceuticals, where he was involved in the development of small-molecule targeted oncology therapies, including the EGFR inhibitor Tarceva. Witt was also a member of OSI's Executive Management Committee starting in 2008.

From 1998 to 2001, he was senior director of Clinical Research & Drug Safety at NeXstar Pharmaceuticals, and continued in that position after NeXstar's acquisition by Gilead Sciences.

Witt worked at Synergen, where he assisted in setting up the company's European headquarters; in 1995, after Amgen purchased Synergen, he continued as a clinical scientist, working primarily on inflammation programmes, including the IL-1ra programme, which subsequently produced Kineret (anakinra).

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now